Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 13/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284094 | 0.87 | ALDH1A1 (0.43) | SMN1; SMN2NPC1ALDH1A1RAB9APTPN1 | |
| SCHEMBL1842933 | 0.83 | PTPN1 (0.59) | HSD11B1PTPN1KDM4E | |
| SCHEMBL263313 | 0.83 | PTPN1 (0.59) | HSD11B1PTPN1KDM4E | |
| SCHEMBL284008 | 0.83 | ALDH1A1 (0.47) | SMN1; SMN2NPC1ALDH1A1RAB9APTPN1 | |
| SCHEMBL269488 | 0.82 | PTPN1 (0.43) | HSD11B1PTPN1 | |
| SCHEMBL284015 | 0.82 | ALDH1A1 (0.40) | SMN1; SMN2NPC1ALDH1A1RAB9APTPN1 | |
| SCHEMBL264109 | 0.79 | CYP17A1 (0.50) | HSD11B1ALDH1A1PTPN1KDM4EHPGD | |
| SCHEMBL21573033 | 0.79 | ALDH1A1 (0.59) | SMN1; SMN2NPC1ALDH1A1RAB9APTPN1 | |
| SCHEMBL3237077 | 0.74 | NPC1 (0.53) | SMN1; SMN2NPC1ALDH1A1RAB9APTPN1 | |
| SCHEMBL29722835 | 0.74 | PTPN1 (0.53) | HSD11B1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134004-B2 | Substituted N-bicyclicalkyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | OPRL1, CNR1, TRPV1 | HSD11B1 2187/4885SMN1; SMN2 1166/4885NPC1 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.